Portfolio company
Immulus
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops manufacturing processes to selectively expand T-cells for drug development for pharmaceutical and biotechnology customers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Tcubeit
This company develops T cell manufacturing platforms and immunotherapy pipelines for pharmaceutical firms and research institutions treating cancer and rare diseases.
Thymmune
This biotechnology company develops scalable thymic cell therapies to restore immune function for patients with immunodeficiencies, autoimmune disorders, and transplant-related conditions.
immunos
This biotechnology company develops immunomodulatory proteins and HLA-based biologic therapies for pharmaceutical companies and healthcare providers to treat cancer and autoimmune diseases.
Immunohelix
Immunohelix develops immune cell-specific oligonucleotide delivery systems and therapeutics for pharmaceutical companies seeking targeted treatments for immunological diseases, infections, and cancers.
Spectacell
This company develops a label-free single-cell analysis platform for pharmaceutical and biotechnology organisations to measure the performance of immune therapies.
immunique
This company develops immune therapeutics, including cell therapies and peptides, for patients with cancer and autoimmune diseases.
Tivic Health
The company develops immunotherapeutic drugs and biomanufacturing services for patients with radiation injury, cancer and age-related immune dysfunction.
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
